Skip to main content
TipRanks
Go Ultimate75% OFF

Celularity (CELU) AI Stock Analysis

219 Followers
CELU

Celularity

(NASDAQ:CELU)

Select Model
Rating:44Neutral
Price Target:$0.61â–¼(-3.02% Downside)
Action:reiterated
Date:10/29/26

The score is primarily weighed down by weak financial performance—sharp revenue decline, heavy operating losses, negative equity, and ongoing cash burn. Technical indicators also point to a weak trend with only tentative oversold support. Corporate events provide some positives (Nasdaq compliance regained; new manufacturing collaboration) but are offset by governance/filing issues and leadership turnover, while valuation lacks support due to losses and no dividend.

Positive Factors
Capability ExpansionThe Vesalius partnership broadens Celularity’s manufacturing platform beyond its traditional placental-derived focus into peptide APIs. If executed, the domestic, traceable production model could add a revenue stream and improve utilization of the company’s complex biologics infrastructure over the medium term.
Negative Factors
Revenue and Profitability CollapseThe sharp revenue contraction leaves the business operating far below the scale needed to support its cost base. Extremely negative operating and net margins show that commercialization has not yet produced sustainable earnings, making a return to break-even dependent on substantial growth or structural cost reductions.

Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%CELU-62.72%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$20.45M
Dividend Yield
―
Average Volume (3M)
3.93M
Price to Earnings (P/E)
-0.4
Beta (1Y)
1.85
Revenue Growth
-58.14%
EPS Growth
47.25%
Country
US
Employees
115
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditio...

Celularity Financial Statement Overview

Summary

Financials remain weak: revenue is sharply lower (TTM $18.7M; -160% growth) and profitability is deeply negative (EBIT/EBITDA margins around -240% and net margin around -248%). While losses and cash burn have improved (net loss narrowed vs 2025; FCF -$8.9M), negative equity (-$35.5M) and continued negative operating cash flow highlight elevated financing/dilution risk.

Income Statement

18Very Negative

Balance Sheet

22Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue18.67M26.55M54.22M22.77M17.98M21.34M
Gross Profit3.59M6.48M39.23M6.75M-1.69M11.68M
EBITDA-36.19M-77.66M-43.71M-183.95M-138.83M-88.11M
Net Income-45.86M-91.72M-57.89M-196.29M14.19M-100.12M
Balance Sheet
Total Assets96.17M107.33M132.68M143.89M401.07M414.13M
Cash, Cash Equivalents and Short-Term Investments586.00K6.17M738.00K227.00K13.97M37.24M
Total Debt36.02M40.90M68.84M65.42M65.59M31.14M
Total Liabilities131.70M145.39M123.84M102.93M202.16M314.71M
Stockholders Equity-35.53M-38.06M8.84M40.96M198.90M99.42M
Cash Flow
Free Cash Flow-8.92M-13.25M-6.56M-42.73M-143.11M-116.30M
Operating Cash Flow-8.92M-13.25M-6.40M-38.69M-137.88M-110.10M
Investing Cash Flow00514.00K-4.05M-5.24M-5.90M
Financing Cash Flow8.38M18.65M6.70M24.09M119.84M98.56M

Celularity Technical Analysis

Technical Analysis SentimentNegative
Last Price0.63

Price Trends

50DMA1.18Negative
100DMA1.02Negative
200DMA1.06Negative

Market Momentum

MACD-0.15Positive
RSI32.47Neutral
STOCH14.36Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 0.63 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 1.18, and below the 200-day MA of 1.06, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 32.47 is Neutral, neither overbought nor oversold. The STOCH value of 14.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.

Celularity Risk Analysis

Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We cannot assure you that the recent reverse stock split will increase our stock price, marketability or our liquidity.Q4, 2023
2.We have material weakness in our internal control over financial reporting, which could adversely affect our business, financial condition and operating results.Q4, 2023
3.We must prioritize development of certain product candidates at the expense of other product candidates given our limited resources. We may choose to expend our limited resources on product candidates that do not yield a successful product and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success..Q4, 2023

Celularity Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CELU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LTRNLTRN44Neutral$6.47M-0.27-456.35%――9.68%
CELUCELU44Neutral$20.45M-0.35142.25%―-58.14%47.25%
STTKSTTK42Neutral$473.57M-9.12-46.46%―-100.00%50.26%
FBLGFBLG40Underperform$6.17M-0.15-536.78%――22.10%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%CELULTRNSTTKFBLGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CELU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CELUCelularity Inc.0.63-1.11-63.79%
LTRNLantern Pharma, Inc.0.43-2.78-86.51%
STTKShattuck Labs, Inc.4.652.64131.34%
FBLGFibroBiologics, Inc.0.93-5.68-85.97%

Celularity Corporate Events

Business Operations and Strategy

Celularity Partners with Vesalius on U.S. Peptide Manufacturing

Positive
Oct 29, 2026

On October 29, 2026, Celularity and Vesalius Longevity Labs announced an exclusive manufacturing collaboration to create a first-of-its-kind U.S.-based final-stage manufacturing and supply platform for Vesalius’s Peptual-branded peptide active pharma...

Business Operations and StrategyExecutive/Board Changes

Celularity adds Naveen Jain amid strategic recapitalization

Positive
Sep 29, 2026

On Sept. 29, 2026, Celularity announced that Naveen Jain, founder and CEO of Viome Life Sciences, will join its Board of Directors following completion of required regulatory procedures. Jain, a serial entrepreneur whose ventures span InfoSpace, Inte...

Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing

Celularity Secures New Convertible Note Financing and Board Shift

Neutral
Sep 28, 2026

On September 23–24, 2026, Celularity Inc. entered into a securities purchase agreement enabling up to $25 million of senior secured convertible notes and accompanying warrants in two tranches and closed an initial $11.01 million tranche at a $1.50 co...

Delistings and Listing ChangesRegulatory Filings and Compliance

Celularity Restores Nasdaq Compliance on Key Listing Standards

Positive
Sep 14, 2026

On September 11, 2026, Celularity Inc. said it had regained compliance with Nasdaq’s minimum bid price requirement and the minimum market value of listed securities standard, leading Nasdaq to close both deficiency matters. The company still faces an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026